“AMBERSAN External counter-pulsation device”
A/ECP_A1, (abbrev. EECP) is a new version of a counter-pulsation device that is developed and manufactured in Taiwan. Using ECG R-wave as the trigger signal, it synchronously controls the cuffs at an early diastolic period.
The cuff pressurizes orderly from the peripheral vessels to the central vessels, enabling the blood flow of the lower limb to return. Before the systolic stage, the cuff (including the bladder) deflates rapidly to open up the pressured vessels of the limbs, to decrease the peripheral circulation resistance and the load to the heart, thereby reducing heart load and reduce myocardial oxygen consumption.
EECP has been proven effective in curing cardiovascular diseases in clinical trials.